Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 202 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents  
EDITORIAL
Year : 2013  |  Volume : 3  |  Issue : 1  |  Page : 1-2  

Bedaquiline: First FDA-approved tuberculosis drug in 40 years


Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

Date of Web Publication18-May-2013

Correspondence Address:
Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151 101, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-516X.112228

Rights and Permissions

How to cite this article:
Mahajan R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int J App Basic Med Res 2013;3:1-2

How to cite this URL:
Mahajan R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int J App Basic Med Res [serial online] 2013 [cited 2018 Nov 17];3:1-2. Available from: http://www.ijabmr.org/text.asp?2013/3/1/1/112228

The US Food and Drug Administration (FDA) on 28 December 2012 granted accelerated approval to Johnson and Johnson's drug bedaquiline to treat resistant tuberculosis (TB), more prevalent in India, China and Eastern Europe. [1] TB remains a global epidemic, with over 2 billion people harboring latent infection and more than 9 million new cases, of which 500,000 are multidrug-resistant (MDR), and nearly 2 million deaths are estimated to occur each year. [2] This mandates discovery of new drugs with novel mechanisms of action to not only shorten the duration of treatment of drug-sensitive TB, but also for treatment of MDR-TB.

TB is a highly infectious disease and is considered one of the world's most serious public health threats. A study in September 2012 published in The Lancet found that almost 44% of patients with TB in countries like Russia, Peru and Thailand showed resistance to at least one second-line drug, or that a medicine used after another drug had already failed. Treating drug-resistant TB can take years and can cost 200 times as much as treating the ordinary form of the disease. Bedaquiline approval was the first time in 40 years that the agency had approved a drug that attacked TB in a different way from the current treatments on the market. The drug, to be called Sirturo, was discovered by scientists at Janssen, the pharmaceuticals unit of Johnson and Johnson, and is the first in a new class of drugs that aims to treat the drug-resistant strain of the disease. [3]

Bedaquiline's unique and specific anti-mycobacterial activity derives from inhibition of the proton pump of mycobacterial ATP synthase. ATP synthase is a critical enzyme in the ATP synthesis of M. tuberculosis. Binding of bedaquiline to the oligomeric and proteolipic subunit-c of mycobacterial ATP synthase leads to inhibition of ATP synthesis, which subsequently results in bacterial death. The gene encoding the subunit-c of the ATP synthase is denoted as atpE and its amino-acid sequence is highly conserved in non-related M. tuberculosis isolates. [2]

However, the drug's potential risks, including increased risk of death, have raised concerns among members of the FDA. About 11.4% of patients taking Sirturo died during clinical trials compared with 2.5% of those taking placebos. As the drug carries some significant risks, it is mandated to be used only in patients who do not have other treatment options. [1] Sirturo carries a so-called black box warning for patients and healthcare professionals that it can affect the heart's electrical activity causing prolongation of the QT interval, which could lead to an abnormal and potentially fatal heart rhythm. Accordingly, the FDA has approved bedaquiline as part of combination therapy to treat adults with MDR pulmonary TB when other alternatives are not available. The FDA also granted fast-track designation, priority review and orphan-product designation to bedaquiline. [4]

The safety and effectiveness of bedaquiline were established in 440 patients in two phase-2 clinical trials. Patients in the first trial were randomly assigned to be treated with bedaquiline plus other drugs used to treat TB, or a placebo plus other drugs used to treat TB. All patients in the second trial received bedaquiline plus other TB drugs. Both studies were designed to measure the time taken for a patient's sputum to be free of M. tuberculosis, known as sputum culture conversion. Results from the first trial showed that patients treated with bedaquiline combination therapy achieved sputum culture conversion in a median time of 83 days, compared with 125 days in patients treated with placebo combination therapy. Results from the second trial showed that the median time to sputum culture conversion was 57 days, supporting the efficacy findings of the first trial. Common side effects identified in the clinical trials included nausea, joint pain and headache. [4]

The company said that although commercial opportunity is very limited, it expects to begin selling bedaquiline in the second quarter of 2013, and will not announce its sales price until then. [1] So, let us keep our fingers crossed!!

 
   References Top

1.Walker J, Tadena N. J and J tuberculosis drug gets fast-track clearance. The Wall Street Journal, 2013 Jan 02. Available from: http://online.wsj.com/article/SB10001424127887323320404578213421059138236.html [Last cited on 2013 Mar 17].  Back to cited text no. 1
    
2.Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010;5:849-58.  Back to cited text no. 2
    
3.Thomas K. FDA approves drug for resistant tuberculosis. Available from: http://www.nytimes.com/2013/01/01/business/fda-approves-new-tuberculosis-drug.html?_r=2 [Last cited on 2013 Mar 18].  Back to cited text no. 3
    
4.US Food and Drug Administration. FDA news release. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm [Last cited on 2013 Mar 18].  Back to cited text no. 4
    



This article has been cited by
1 Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy
Julie Laborde,Céline Deraeve,Francisca Gilmara de Mesquita Vieira,Alix Sournia-Saquet,Lionel Rechignat,Anne Drumond Villela,Bruno Lopes Abbadi,Fernanda Souza Macchi,Kenia Pissinate,Cristiano V. Bizarro,Pablo Machado,Luiz Augusto Basso,Geneviève Pratviel,Luiz Gonzaga de França Lopes,Eduardo Henrique Silva Sousa,Vania Bernardes-Génisson
Journal of Inorganic Biochemistry. 2018; 179: 71
[Pubmed] | [DOI]
2 Scientific rationale for traditional use of plants to treat tuberculosis in the eastern region of the OR Tambo district, South Africa
B. Madikizela,L.J. McGaw
Journal of Ethnopharmacology. 2018; 224: 250
[Pubmed] | [DOI]
3 Alkylated/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: Synthesis and anti-mycobacterial evaluation
Vincent Shalini,Albertus Viljoen,Laurent Kremer,Vipan Kumar
Bioorganic & Medicinal Chemistry Letters. 2018;
[Pubmed] | [DOI]
4 In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis
Sukyung Kim,Hoonhee Seo,Hafij Al Mahmud,Md Imtiazul Islam,Byung-Eui Lee,Myoung-Lae Cho,Ho-Yeon Song
Phytomedicine. 2018;
[Pubmed] | [DOI]
5 Total Synthesis and Conformational Study of Callyaerin A: Anti-Tubercular Cyclic Peptide Bearing a Rare Rigidifying (Z )-2,3- Diaminoacrylamide Moiety
Shengping Zhang,Luis M. De Leon Rodriguez,Ivanhoe K. H. Leung,Gregory M. Cook,Paul W. R. Harris,Margaret A. Brimble
Angewandte Chemie International Edition. 2018;
[Pubmed] | [DOI]
6 Total Synthesis and Conformational Study of Callyaerin A: Anti-Tubercular Cyclic Peptide Bearing a Rare Rigidifying (Z )-2,3- Diaminoacrylamide Moiety
Shengping Zhang,Luis M. De Leon Rodriguez,Ivanhoe K. H. Leung,Gregory M. Cook,Paul W. R. Harris,Margaret A. Brimble
Angewandte Chemie. 2018;
[Pubmed] | [DOI]
7 Design, Synthesis, and in vitro antitubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives
Saleha Banu,Rajitha Bollu,Lingaiah Nagarapu,Jagadeesh Babu Nanubolu,Perumal Yogeswari,Dharmarajan Sriram,Shravan Kumar Gunda,Divyasphoorthi Vardhan
Chemical Biology & Drug Design. 2018;
[Pubmed] | [DOI]
8 Mycobacterial protein tyrosine kinase, PtkA phosphorylates PtpA at tyrosine residues and the mechanism is stalled by the novel series of inhibitors
Swati Jaiswal,Aditi Chatterjee,Sapna Pandey,Kiran Lata,Ranjith Kumar Gadi,Rajesh Manda,Sanjay Kumar,Maddi Sridhar Reddy,Ravishankar Ramachandran,Kishore K. Srivastava
Journal of Drug Targeting. 2018; : 1
[Pubmed] | [DOI]
9 Rational design of isonicotinic acid hydrazide derivatives with antitubercular activity: Machine learning, molecular docking, synthesis and biological testing
Vasyl Kovalishyn,Julie Grouleff,Ivan Semenyuta,Vitaliy O. Sinenko,Sergiy R. Slivchuk,Diana Hodyna,Volodymyr Brovarets,Volodymyr Blagodatny,Gennady Poda,Igor V. Tetko,Larysa Metelytsia
Chemical Biology & Drug Design. 2018;
[Pubmed] | [DOI]
10 Tomatidine Is a Lead Antibiotic Molecule That Targets Staphylococcus aureus ATP Synthase Subunit C
Maxime Lamontagne Boulet,Charles Isabelle,Isabelle Guay,Eric Brouillette,Jean-Philippe Langlois,Pierre-Étienne Jacques,Sébastien Rodrigue,Ryszard Brzezinski,Pascale B. Beauregard,Kamal Bouarab,Kumaraswamy Boyapelly,Pierre-Luc Boudreault,Éric Marsault,François Malouin
Antimicrobial Agents and Chemotherapy. 2018; 62(6): e02197-17
[Pubmed] | [DOI]
11 Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold
Urja Nimbalkar,Julio Seijas,Rachna Borkute,Manoj Damale,Jaiprakash Sangshetti,Dhiman Sarkar,Anna Nikalje
Molecules. 2018; 23(8): 1945
[Pubmed] | [DOI]
12 Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
Diana Machado,Miriam Girardini,Miguel Viveiros,Marco Pieroni
Frontiers in Microbiology. 2018; 9
[Pubmed] | [DOI]
13 Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach
Ramón Soto,Esther Perez-Herran,Beatriz Rodriguez,Bogdan M. Duma,Monica Cacho-Izquierdo,Alfonso Mendoza-Losana,Joel Lelievre,David Barros Aguirre,Lluis Ballell,Liam R. Cox,Luke J. Alderwick,Gurdyal S. Besra
Scientific Reports. 2018; 8(1)
[Pubmed] | [DOI]
14 Slow-Binding Inhibition of Mycobacterium tuberculosis Shikimate Kinase by Manzamine Alkaloids
Johayra Simithy,Ngolui Rene Fuanta,Mansour Alturki,Judith V. Hobrath,Amir E. Wahba,Ivett Pina,Jnanendra Rath,Mark T. Hamann,Jack DeRuiter,Douglas C. Goodwin,Angela I. Calderón
Biochemistry. 2018; 57(32): 4923
[Pubmed] | [DOI]
15 Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis
Ana-Maria Ionescu,Abela Mpobela Agnarson,Chrispin Kambili,Laurent Metz,Jonathan Kfoury,Steven Wang,Abeda Williams,Vikram Singh,Adrian Thomas
Expert Review of Pharmacoeconomics & Outcomes Research. 2018; : 1
[Pubmed] | [DOI]
16 Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery
Elisa Azzali,Diana Machado,Amit Kaushik,Federica Vacondio,Sara Flisi,Clotilde Silvia Cabassi,Gyanu Lamichhane,Miguel Viveiros,Gabriele Costantino,Marco Pieroni
Journal of Medicinal Chemistry. 2017;
[Pubmed] | [DOI]
17 Preliminary SAR and biological evaluation of antitubercular triazolothiadiazine derivatives against drug-susceptible and drug-resistant Mtb strains
Ziqiang Li,Xiaoguang Bai,Qi Deng,Guoning Zhang,Lei Zhou,Yishuang Liu,Juxian Wang,Yucheng Wang
Bioorganic & Medicinal Chemistry. 2017; 25(1): 213
[Pubmed] | [DOI]
18 High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities
Jinyeong Heo,Jiyoun Nam,Jichan Jang,David Shum,Constantin Radu,Jinhua Cheng,Hanki Lee,Joo-Won Suh,Vincent Delorme
SLAS Discovery. 2017; 22(2): 144
[Pubmed] | [DOI]
19 Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’
Yoshiaki Takahashi,Masayuki Igarashi
The Journal of Antibiotics. 2017;
[Pubmed] | [DOI]
20 Synergistic Response of Rifampicin with Hydroperoxides on Mycobacterium: A Mechanistic Study
Yesha S. Patel,Sarika Mehra
Frontiers in Microbiology. 2017; 8
[Pubmed] | [DOI]
21 Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Vahid Lohrasbi,Malihe Talebi,Abed Zahedi Bialvaei,Lanfranco Fattorini,Michel Drancourt,Mohsen Heidary,Davood Darban-Sarokhalil
Tuberculosis. 2017;
[Pubmed] | [DOI]
22 Genomic Insight into Mechanisms of Reversion of Antibiotic Resistance in Multidrug Resistant Mycobacterium tuberculosis Induced by a Nanomolecular Iodine-Containing Complex FS-1
Aleksandr I. Ilin,Murat E. Kulmanov,Ilya S. Korotetskiy,Rinat A. Islamov,Gulshara K. Akhmetova,Marina V. Lankina,Oleg N. Reva
Frontiers in Cellular and Infection Microbiology. 2017; 7
[Pubmed] | [DOI]
23 Synthesis, biological evaluation, and molecular docking studies of novel 3-aryl-5-(alkyl-thio)-1H -1,2,4-triazoles derivatives targeting Mycobacterium tuberculosis
Navnath D. Rode,Amol D. Sonawane,Laxman Nawale,Vijay M. Khedkar,Ramesh A. Joshi,Anjali P. Likhite,Dhiman Sarkar,Rohini R. Joshi
Chemical Biology & Drug Design. 2017;
[Pubmed] | [DOI]
24 Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis
Ji-Chan Jang,Yong-Gyun Jung,Jungil Choi,Hyunju Jung,Sungweon Ryoo
Journal of Microbiology. 2017;
[Pubmed] | [DOI]
25 A temporal proteome dynamics study reveals the molecular basis of induced phenotypic resistance in Mycobacterium smegmatis at sub-lethal rifampicin concentrations
Alexander D. Giddey,Elise de Kock,Kehilwe C. Nakedi,Shaun Garnett,Andrew J. M. Nel,Nelson C. Soares,Jonathan M. Blackburn
Scientific Reports. 2017; 7: 43858
[Pubmed] | [DOI]
26 Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2- c ]pyridine Mannich bases
Gilish Jose,Tholappanavara H. Suresha Kumara,Haliwana B.V. Sowmya,Dharmarajan Sriram,Tayur N. Guru Row,Amar A. Hosamani,Sunil S. More,Bhavya Janardhan,B.G. Harish,Sandeep Telkar,Yalegara Siddappa Ravikumar
European Journal of Medicinal Chemistry. 2017; 131: 275
[Pubmed] | [DOI]
27 N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-transEnoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity
Ana Guardia,Gulcin Gulten,Raquel Fernandez,Jesus Gómez,Feng Wang,Maire Convery,Delia Blanco,María Martínez,Esther Pérez-Herrán,Marta Alonso,Fátima Ortega,Joaquín Rullás,David Calvo,Lydia Mata,Robert Young,James C. Sacchettini,Alfonso Mendoza-Losana,Modesto Remuiñán,Lluís Ballell Pages,Julia Castro-Pichel
ChemMedChem. 2016; : n/a
[Pubmed] | [DOI]
28 Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway
Subramanyam J. Tantry,Vikas Shinde,Gayathri Balakrishnan,Shankar D. Markad,Amit K. Gupta,Jyothi Bhat,Ashwini Narayan,Anandkumar Raichurkar,Lalit Kumar Jena,Sreevalli Sharma,Naveen Kumar,Robert Nanduri,Sowmya Bharath,Jitendar Reddy,Vijender Panduga,K. R. Prabhakar,Karthikeyan Kandaswamy,Parvinder Kaur,Neela Dinesh,Supreeth Guptha,Ramanatha Saralaya,Manoranjan Panda,Suresh Rudrapatna,Meenakshi Mallya,Harvey Rubin,Takahiro Yano,Khisi Mdluili,Christopher B. Cooper,V. Balasubramanian,Vasan K. Sambandamurthy,Vasanthi Ramachandran,Radha Shandil,Stefan Kavanagh,Shridhar Narayanan,Pravin Iyer,Kakoli Mukherjee,Vinayak P. Hosagrahara,Suresh Solapure,Shahul Hameed P,Sudha Ravishankar
Med. Chem. Commun.. 2016;
[Pubmed] | [DOI]
29 Crystal structure ofMycobacterium tuberculosisketol-acid reductoisomerase at 1.0 Å resolution - a potential target for anti-tuberculosis drug discovery
You Lv,Ajit Kandale,Shun Jie Wun,Ross P. McGeary,Simon J. Williams,Bostjan Kobe,Volker Sieber,Mark A. Schembri,Gerhard Schenk,Luke W. Guddat
FEBS Journal. 2016; 283(7): 1184
[Pubmed] | [DOI]
30 Viability, morphology, and proteome ofMycobacterium smegmatis MSMEG_0319knockout strain
Shanshan Sha,Xiaoxia Shi,Liming Xu,Jiabin Wen,Yi Xin,Yufang Ma
PROTEOMICS. 2016; 16(7): 1090
[Pubmed] | [DOI]
31 Design, synthesis and biological evaluation of novel quinoline-based carboxylic hydrazides as anti-tubercular agents
Subhash Chander,Penta Ashok,Davie Cappoen,Paul Cos,Sankaranarayanan Murugesan
Chemical Biology & Drug Design. 2016;
[Pubmed] | [DOI]
32 Synthesis and antitubercular and antibacterial activity of some active fluorine containing quinoline–pyrazole hybrid derivatives
Nagabhushana Nayak,Jurupula Ramprasad,Udayakumar Dalimba
Journal of Fluorine Chemistry. 2016; 183: 59
[Pubmed] | [DOI]
33 The pregnane X receptor in tuberculosis therapeutics
Amina I Shehu,Guangming Li,Wen Xie,Xiaochao Ma
Expert Opinion on Drug Metabolism & Toxicology. 2016; 12(1): 21
[Pubmed] | [DOI]
34 Emerging drugs and alternative possibilities in the treatment of tuberculosis
S. Hofman,M.M. Segers,S. Ghimire,M.S. Bolhuis,M.G.G. Sturkenboom,D. Van Soolingen,J.W.C. Alffenaar
Expert Opinion on Emerging Drugs. 2016; : 1
[Pubmed] | [DOI]
35 Synthesis, oxidation potential and anti-mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism
Julie Laborde,Céline Deraeve,Léa Lecoq,Alix Sournia-Saquet,Jean-Luc Stigliani,Beatrice S. Orena,Giorgia Mori,Geneviève Pratviel,Vania Bernardes-Génisson
ChemistrySelect. 2016; 1(2): 172
[Pubmed] | [DOI]
36 Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors
Brahmam Medapi,Nikhila Meda,Pushkar Kulkarni,Perumal Yogeeswari,Dharmarajan Sriram
Bioorganic & Medicinal Chemistry. 2016; 24(4): 877
[Pubmed] | [DOI]
37 Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent
Mubarak H. Shaikh,Dnyaneshwar D. Subhedar,Manisha Arkile,Vijay M. Khedkar,Nandadeep Jadhav,Dhiman Sarkar,Bapurao B. Shingate
Bioorganic & Medicinal Chemistry Letters. 2016; 26(2): 561
[Pubmed] | [DOI]
38 Identification of a novel class of quinoline–oxadiazole hybrids as anti-tuberculosis agents
Puneet P. Jain,Mariam S. Degani,Archana Raju,Aarti Anantram,Madhav Seervi,Sadhana Sathaye,Muktikanta Ray,M.G.R. Rajan
Bioorganic & Medicinal Chemistry Letters. 2016; 26(2): 645
[Pubmed] | [DOI]
39 Discovery of in vitro antitubercular agents through in silico ligand-based approaches
Daniela De Vita,Fabiana Pandolfi,Roberto Cirilli,Luigi Scipione,Roberto Di Santo,Laura Friggeri,Mattia Mori,Diego Fiorucci,Giorgio Maccari,Robert Selwyne Arul Christopher,Claudio Zamperini,Valentina Pau,Alessandro De Logu,Silvano Tortorella,Maurizio Botta
European Journal of Medicinal Chemistry. 2016; 121: 169
[Pubmed] | [DOI]
40 Structure, Dynamics, and Interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 Examined by Molecular Modeling, Simulation, and Electrostatic Studies
Isha Bhutani,Saurabh Loharch,Pawan Gupta,Rethi Madathil,Raman Parkesh,Chandra Verma
PLOS ONE. 2015; 10(3): e0119771
[Pubmed] | [DOI]
41 Complete Genome Sequence of Multidrug-Resistant Clinical IsolateMycobacterium tuberculosis187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1
Aleksandr I. Ilin,Murat E. Kulmanov,Ilya S. Korotetskiy,Gulshara K. Akhmetova,Marina V. Lankina,Sergey V. Shvidko,Oleg N. Reva
Genome Announcements. 2015; 3(6): e01272-15
[Pubmed] | [DOI]
42 Bedaquiline and delamanid in tuberculosis
Susanna Esposito,Sonia Bianchini,Francesco Blasi
Expert Opinion on Pharmacotherapy. 2015; 16(15): 2319
[Pubmed] | [DOI]
43 Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents
Bharathkumar Inturi,Gurubasavaraj V. Pujar,Madhusudhan N. Purohit
Journal of Receptors and Signal Transduction. 2015; 35(5): 468
[Pubmed] | [DOI]
44 Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease
Julie V. Philley,Richard J. Wallace,Jeana L. Benwill,Varsha Taskar,Barbara A. Brown-Elliott,Foram Thakkar,Timothy R. Aksamit,David E. Griffith
Chest. 2015; 148(2): 499
[Pubmed] | [DOI]
45 Current perspectives in drug discovery against tuberculosis from natural products
Joseph Mwanzia Nguta,Regina Appiah-Opong,Alexander K. Nyarko,Dorothy Yeboah-Manu,Phyllis G.A. Addo
International Journal of Mycobacteriology. 2015; 4(3): 165
[Pubmed] | [DOI]
46 Design, Synthesis, and Biological Evaluation of New 8-Trifluoromethylquinoline Containing Pyrazole-3-carboxamide Derivatives
Nagabhushana Nayak,Jurupula Ramprasad,Udayakumar Dalimba
Journal of Heterocyclic Chemistry. 2015; : n/a
[Pubmed] | [DOI]
47 Anything to Stay Alive: The Challenges of a Campaign for an Experimental Drug
Nathan Geffen
Developing World Bioethics. 2015; : n/a
[Pubmed] | [DOI]
48 Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen
Anita Ordas,Robert-Jan Raterink,Fraser Cunningham,Hans J. Jansen,Malgorzata I. Wiweger,Susanne Jong-Raadsen,Sabine Bos,Robert H. Bates,David Barros,Annemarie H. Meijer,Rob J. Vreeken,Lluís Ballell-Pages,Ron P. Dirks,Thomas Hankemeier,Herman P. Spaink
Antimicrobial Agents and Chemotherapy. 2015; 59(2): 753
[Pubmed] | [DOI]
49 Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design
Marco Pieroni,Baojie Wan,Valentina Zuliani,Scott G. Franzblau,Gabriele Costantino,Mirko Rivara
European Journal of Medicinal Chemistry. 2015; 100: 44
[Pubmed] | [DOI]
50 Novel isoniazid–amidoether derivatives: synthesis, characterization and antimycobacterial activity evaluation
Deepak Kumar,Garima Khare,Beena Beena,Saqib Kidwai,Anil K. Tyagi,Ramandeep Singh,Diwan S. Rawat
Med. Chem. Commun.. 2015; 6(1): 131
[Pubmed] | [DOI]
51 Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors
Manoj Chandran,Janupally Renuka,Jonnalagadda Padma Sridevi,Ganesh S. Pedgaonkar,Vanaparthi Asmitha,Perumal Yogeeswari,Dharmarajan Sriram
International Journal of Mycobacteriology. 2015;
[Pubmed] | [DOI]
52 Trends in discovery of new drugs for tuberculosis therapy
Giovanna Riccardi,Maria Rosalia Pasca
The Journal of Antibiotics. 2014;
[Pubmed] | [DOI]
53 Diagnosis and treatment of multidrug-resistant tuberculosis
Young Ae Kang
Journal of the Korean Medical Association. 2014; 57(1): 27
[Pubmed] | [DOI]
54 TB Summit 2014: Prevention, diagnosis, and treatment of tuberculosis—a meeting report of a Euroscicon conference
Arundhati Maitra,Sanjib Bhakta
Virulence. 2014; 5(5): 638
[Pubmed] | [DOI]
55 Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation
Deepak Kumar,Deepak Beena,Garima Khare,Saqib Kidwai,Anil K. Tyagi,Ramandeep Singh,Diwan S. Rawat
European Journal of Medicinal Chemistry. 2014;
[Pubmed] | [DOI]
56 Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates
Garrett C. Moraski,Allen G. Oliver,Lowell D. Markley,Sanghyun Cho,Scott G. Franzblau,Marvin J. Miller
Bioorganic & Medicinal Chemistry Letters. 2014;
[Pubmed] | [DOI]
57 Synthesis and evaluation of anti-tubercular activity of 6-(4-substitutedpiperazin-1-yl) phenanthridine analogues
Hunsur Nagendra Nagesh,Narva Suresh,Kalaga Mahalakshmi Naidu,Boyineni Arun,Jonnalagadda Padma Sridevi,Dharmarajan Sriram,Perumal Yogeeswari,Kondapalli Venkata Gowri Chandra Sekhar
European Journal of Medicinal Chemistry. 2014;
[Pubmed] | [DOI]
58 Design, synthesis and antimycobacterial activity of various 3-(4-(substitutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives
Kalaga Mahalakshmi Naidu,Amaroju Suresh,Jayanty Subbalakshmi,Dharmarajan Sriram,Perumal Yogeeswari,Pallepogu Raghavaiah,Kondapalli Venkata Gowri Chandra Sekhar
European Journal of Medicinal Chemistry. 2014; 87: 71
[Pubmed] | [DOI]
59 Whole-Cell Screening-Based Identification of Inhibitors against the Intraphagosomal Survival of Mycobacterium tuberculosis
Garima Khare,Praveen Kumar,Anil K. Tyagi
Antimicrobial Agents and Chemotherapy. 2013; 57(12): 6372
[Pubmed] | [DOI]
60 Design, synthesis and evaluation of 6-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenanthridine analogues as antimycobacterial agents
Hunsur Nagendra Nagesh,Kalaga Mahalakshmi Naidu,Damarla Harika Rao,Jonnalagadda Padma Sridevi,Dharmarajan Sriram,Perumal Yogeeswari,Kondapalli Venkata Gowri Chandra Sekhar
Bioorganic & Medicinal Chemistry Letters. 2013;
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed3788    
    Printed100    
    Emailed2    
    PDF Downloaded805    
    Comments [Add]    
    Cited by others 60    

Recommend this journal